Inmune Bio, Inc. financial data

Symbol
INMB on Nasdaq
Location
Boca Raton, FL
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 30 Oct 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 355% % 63%
Debt-to-equity 28% % -41%
Return On Assets -134% % -70%
Operating Margin -26210% % -152%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 26,585,258 shares 20%
Common Stock, Shares, Outstanding 26,585,258 shares 20%
Entity Public Float $135,000,000 USD 27%
Common Stock, Value, Issued $27,000 USD 23%
Weighted Average Number of Shares Outstanding, Basic 26,585,258 shares 32%
Weighted Average Number of Shares Outstanding, Diluted 26,585,258 shares 32%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $50,000 USD 257%
Research and Development Expense $25,683,000 USD -19%
General and Administrative Expense $9,229,000 USD -5.5%
Operating Income (Loss) $51,376,000 USD -24%
Nonoperating Income (Expense) $961,000 USD 398%
Net Income (Loss) Attributable to Parent $49,887,000 USD -21%
Earnings Per Share, Basic -2 USD/shares 2.8%
Earnings Per Share, Diluted -2 USD/shares 2.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $27,734,000 USD -17%
Accounts Receivable, after Allowance for Credit Loss, Current $1,704,000 USD 54%
Assets, Current $30,670,000 USD -14%
Property, Plant and Equipment, Net $878,000 USD
Operating Lease, Right-of-Use Asset $1,064,000 USD 218%
Intangible Assets, Net (Excluding Goodwill) $16,514,000 USD 0%
Other Assets, Noncurrent $746,000 USD 810%
Assets $33,358,000 USD -37%
Liabilities, Current $7,357,000 USD -47%
Operating Lease, Liability, Noncurrent $623,000 USD 119%
Liabilities $7,980,000 USD -43%
Accumulated Other Comprehensive Income (Loss), Net of Tax $764,000 USD 26%
Retained Earnings (Accumulated Deficit) $203,773,000 USD -32%
Stockholders' Equity Attributable to Parent $25,378,000 USD -34%
Liabilities and Equity $33,358,000 USD -37%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $6,824,000 USD 8.7%
Net Cash Provided by (Used in) Financing Activities $5,274,000 USD
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 26,585,258 shares 20%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,585,000 USD 84%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $27,734,000 USD -17%
Interest Paid, Excluding Capitalized Interest, Operating Activities $302,000 USD -33%
Deferred Tax Assets, Valuation Allowance $25,688,000 USD 31%
Deferred Tax Assets, Gross $25,700,000 USD 31%
Operating Lease, Liability $1,080,000 USD 158%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $49,615,000 USD -19%
Lessee, Operating Lease, Liability, to be Paid $1,202,000 USD
Operating Lease, Liability, Current $457,000 USD 239%
Lessee, Operating Lease, Liability, to be Paid, Year Two $405,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $729,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $122,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $51,000 USD -74%
Deferred Tax Assets, Operating Loss Carryforwards $8,686,000 USD 27%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Operating Lease, Payments $152,000 USD
Additional Paid in Capital $229,888,000 USD 19%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $545,000 USD
Share-based Payment Arrangement, Expense $2,984,000 USD 74%
Interest Expense $0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%